NutrigeneAI Invited to Participate in the 2026 Asia Summit on Global Health

NutrigeneAI Invited to Participate in the 2026 Asia Summit on Global Health
Representing One of The Chinese University of Hong Kong's Top Ten Innovation Projects, the Company Will Exhibit and Present at the Summit

Hong Kong, 7 May 2026 — NutrigeneAI Biotech Limited ("NutrigeneAI"), a selected top-ten innovation project from The Chinese University of Hong Kong (CUHK), has been officially invited to participate in the **6th Asia Summit on Global Health (ASGH)**, which will be held at the Hong Kong Convention and Exhibition Centre (HKCEC) from **11 to 12 May 2026**.

Against the backdrop of rapid scientific advancement, growing geopolitical complexity, and rising medical demand, global health challenges can no longer be addressed by any single country, enterprise, or institution alone. Recognised as a premier event for medical and healthcare innovation in Asia, ASGH 2026 will be held under the theme **"Fuelling Healthcare Breakthroughs"**. Jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), the summit will bring together global decision-makers, including policymakers, Nobel laureates such as **Prof. Michael Levitt**, a 2013 Nobel Prize laureate in Chemistry, senior executives, investors, and biotechnology founders, to explore the future of global healthcare.

This year's summit will echo China's launch of the **15th Five-Year Plan**, with medical and healthcare — particularly biomanufacturing and advanced biopharmaceutical innovation — being elevated as a key national strategic priority. This will create important policy cycles and industry opportunities for the biopharmaceutical and medical device sectors. The summit will feature high-level plenary sessions, fireside chats, workshops, the **InnoHealth Showcase** innovation exhibition area with approximately 180 dedicated booths, and Deal-making matching sessions. Topics will cover global health security preparedness in the post-pandemic era, translational pathways for breakthrough innovations, frontier developments in AI and computational biology, the new landscape of China's healthcare sector, and the standardisation of traditional Chinese and Western medicine integration. The event aims to strengthen Hong Kong's role as Asia's "super connector", facilitating cross-border collaboration, innovation implementation, and technology commercialisation.

NutrigeneAI will set up an independent project booth at the **InnoHealth Showcase** exhibition area (**3F-C18**) and will also exhibit alongside the CUHK booth (**3F-C06**), showcasing its breakthrough innovation in the field of vascular regenerative medicine. Meanwhile, the company has been selected as one of the pitching projects

and will deliver a live presentation at the **Pitching Sequence 6** session under **Pharmaceutical & Community Health** on **11 May, from 16:30 to 17:45, at Hall 3F Open Stage**, introducing its core technology and commercialisation potential to international investors, industry leaders, and medical experts.



During the summit, NutrigeneAI will also join the **ASGH Deal-making** platform at **www.asghdealmaking.com**. Global investors, partners, and industry participants are welcome to schedule **on-site one-on-one meetings** through the platform from **11 to 12 May, 09:00–18:00, at Hall 3F-G**, or arrange **online meetings** from **13 to 14 May, 09:00–22:00**, to jointly explore collaboration and investment opportunities.

NutrigeneAI sincerely invites professionals from all sectors to visit its booth, engage in discussions, and attend its roadshow presentation, to witness how innovative cell therapies can bring new momentum to global vascular health.

Event Details

Date & Opening Hours:	11-12 May 2026 (Mon-Tue) 09:00 – 18:00
Location:	Hall 3F-G, Hong Kong Convention and Exhibition Centre (HKCEC), Wanchai, Hong Kong
CUHK Booth no.:	3F-C06
Your Project Booth no.:	3F-C18
Official website:	https://www.asiasummitglobalhealth.com/conference/asgh/en

About NutrigeneAI

NutrigeneAI Biotech Limited is an innovative biotechnology company co-founded in November 2023 by Professor Wing Tak Jack Wong of The Chinese University of Hong

Kong and Mr. Gary Ng, Chief Financial Officer. The company is led by Dr. Wang, who has extensive industry experience, as CEO. NutrigeneAI focuses on the development and commercialisation of next-generation biotechnology platforms derived from CUHK's cutting-edge research. Its core technology centres on **induced pluripotent stem cell-derived functionally enhanced endothelial cell therapy (iPSC-EC)** and the development of a globally leading **Type II cytokine pre-activation technology platform**.



This technology breaks through the limitations of traditional mesenchymal stem cells (MSCs), whose therapeutic effects mainly rely on paracrine secretion. NutrigeneAI's enhanced endothelial cells can directly integrate into damaged blood vessels and enable a transition from "signal modulation" to "structural repair". Preclinical studies have shown that in murine models of lower-limb ischaemia, the therapy can increase blood flow recovery to 150% and simultaneously promote 100% vascular network formation, significantly enhancing angiogenesis, anti-inflammatory activity, and tissue repair capacity. The company adopts an **HLA-matched allogeneic cell strategy** to reduce the risk of immune rejection and improve suitability for Asian population characteristics.

Guided by its mission of **"Repairing Life's Pipelines And Reshaping Vascular Health"**, NutrigeneAI focuses on major vascular diseases, including peripheral artery disease (PAD), critical limb ischemia (CLI), diabetic foot ulceration, erectile dysfunction (ED), and ischemic stroke. The company has established in-depth collaborations with leading medical institutions and expert teams, including Shanghai First People's Hospital, Shenzhen People's Hospital, West China Hospital, as well as cardiology and thoracic surgery teams at The Chinese University of Hong Kong. NutrigeneAI plans to launch investigator-initiated clinical trials (IITs) by the end of 2026. It has also received funding support from multiple government agencies in Hong Kong and Shenzhen, completed Pre-A round financing, and is accelerating its GMP-grade cell manufacturing, GLP toxicology studies, and IND submissions in China and the United States, with the goal of achieving product commercialisation and an IPO in Hong Kong or the United States by 2030.

As one of CUHK's selected top-ten representative innovation projects, NutrigeneAI's invitation to participate in the 2026 Asia Summit on Global Health not only reflects recognition of the company's technological innovation capabilities, but also provides an important platform for deeper collaboration with global investors, medical institutions, and industry partners.

Event Information

- **Date & Time:** 11–12 May 2026, Monday–Tuesday, 09:00–18:00
- **Venue:** Hall 3F-G, Hong Kong Convention and Exhibition Centre
- **Official Website:** https://www.asiasummitglobalhealth.com

For more information or to schedule a visit, please contact NutrigeneAI Business Development Manager **Mr. Ke** at **18080939352**.